Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

Expert Opinion on Investigational Drugs

Volumn 10, Issue 5, 2001, Pages 825-834

  Paranjape, S B ^a   Thibonnier, M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaretics; Arterial hypertension; Congestive heart failure; Dysmenorrhoea; Hyponatraemia; Liver cirrhosis; Non peptide receptor antagonists; Ocular hypertension; SIADH; Vasopressin; Vasopressin receptors

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; AQUAPORIN 2; BETA ENDORPHIN; CLONIDINE; CONIVAPTAN; CORTICOTROPIN; CYCLIC AMP; FUROSEMIDE; HORMONE; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; NONAPEPTIDE; OXYTOCIN RECEPTOR; PLACEBO; PROSTAGLANDIN F2 ALPHA; RECEPTOR SUBTYPE; RELCOVAPTAN; SR 121463 A; TIMOLOL; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V3 RECEPTOR; VP 343; WATER; YM 0887;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SCREENING; DYSMENORRHEA; GLAUCOMA; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INTRAOCULAR HYPERTENSION; LIQUID; LIVER CIRRHOSIS; NEPHROTIC SYNDROME; NONHUMAN; OSMOLALITY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RAT; RAYNAUD PHENOMENON; RECEPTOR AFFINITY; REVIEW; SIDE EFFECT; TUMOR; VASOCONSTRICTION; WATER ABSORPTION; WATER RETENTION;

ADMINISTRATION, ORAL; ANIMALS; DIABETES INSIPIDUS; DYSMENORRHEA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; HYPONATREMIA; RECEPTORS, VASOPRESSIN;

EID: 0035013571     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.5.825     Document Type: Review

References (72)

1. The organization of oxytocin and vasopressin pathways
2. Thirst and brain control of water balance
3. Median preoptic nucleus projections to vasopressin-containing neurones of the supraoptic nucleus in sheep. A light and electron microscopic study
4. Thirst and vasopressin function in normal and disordered states of water balance
5. Antidiuretic hormone and the factors which determine its release
6. The regulation of vasopressin function in health and disease
7. Nonosmolar control of renal water excretion
8. Osmotic and nonosmotic control of vasopressin release
9. Baroreceptor influences on oxytocin and vasopressin secretion
10. Molecular pharmacology of human vasopressin receptors
11. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists
12. 1-vascular vasopressin receptors
13. 1-vascular vasopressin receptors
14. 1-vascular vasopressin receptors
15. Molecular and cellular biology of vasopressin and oxytocin receptors and action in the kidney
16. Extrapituitary expression of the rat V1b vasopressin receptor gene
17. 3-pituitary receptor: Ligand-binding profile and density-dependent signaling pathways
18. Molecular cloning of the receptor for human antidiuretic hormone
19. Molecular cloning, sequencing and functional expression of a cDNA encoding the human V1a vasopressin receptor
20. 3-pituitary vasopressin receptor
21. Increased plasma arginine-vasopressin levels in patients with congestive heart failure
22. Vasopressin and blood pressure regulation
23. Primary dysmenorrhoea and vasopressin
24. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat
25. Hemodynamic effects of infused arginine vasopressin in congestive heart failure
26. Salt-induced hypertension the interactive roles of vasopressin and of the sympathetic nervous system
27. Antagonists of vasopressin and oxytocin: Current status and future perspectives
28. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin
29. Anomalous antidiuretic activity of antidiuretic hormone antagonists
30. 1 receptor antagonist
31. Aquaretics
32. The treatment of hyponatremia using vasopressin antagonists
33. 1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers
34. Biochemical and pharmacological properties of SR-49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors
35. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients
36. Endocrine control of salt and water excretion: The role of vasopressin in DOCA-salt hypertension
37. Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells
38. Vasopressin as vasopressor
39. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison with the renin-angiotensin system and the sympathetic system
40. Clinical studies with a vascular vasopressin antagonist
41. Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure
42. 1a vasopressin receptor antagonist, in Raynaud's phenomenon
43. Effects of the vasopressin V1a receptor antagonist, SR-49059, on the response of human uterine arteries to vasopressin and other vasoactive substances
44. Effects of SR-49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions
45. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea
46. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist
47. Renal water handling in rats with decompensated liver cirrhosis
48. Comparison of two aquaretic drugs (Niravoline and OPC-31260) in cirhrotic rats with ascites and water retention
49. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
50. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
51. 2 receptor antagonist
52. 2 vasopressin receptor antagonist. SR121463, in cirrhotic rats
53. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino) benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist
54. 2 receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
55. Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized, double-blind trial
56. 2 receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure
57. Urinary excretion of aquaporin-2 in humans: A potential marker of collecting duct responsiveness to vasopressin
58. 2 receptor antagonist, in rats
59. 2 receptor antagonist, in a rabbit model of ocular hypertension
60. Congenital nephrogenic diabetes insipidus
61. 2 vasopressin receptor mutants
62. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure
63. Evidence against a pressor role for vasopressin in spontaneous hypertension
64. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist
65. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction
66. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
67. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo
68. 2 receptor antagonist (YM087) in the rat
69. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1a and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
70. 2 vasopressin receptor antagonist in normal subjects
71. Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1a and V2 receptor antagonist in patients with advanced heart failure
72. Urinary water clearance after infusion of Conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure